GSK (LON:GSK) Issues Quarterly Earnings Results

GSK (LON:GSK) released its quarterly earnings results on Wednesday. The company reported GBX 23.20 ($0.29) earnings per share (EPS) for the quarter, Digital Look Earnings reports. GSK had a return on equity of 33.30% and a net margin of 12.83%.

GSK Price Performance

GSK stock traded up GBX 103.22 ($1.29) during midday trading on Wednesday, reaching GBX 1,483.22 ($18.51). The company had a trading volume of 72,468,234 shares, compared to its average volume of 33,657,906. The company has a market capitalization of £60.52 billion, a price-to-earnings ratio of 1,312.59, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. The company has a debt-to-equity ratio of 123.04, a current ratio of 0.82 and a quick ratio of 0.73. GSK has a 1-year low of GBX 1,282.50 ($16.01) and a 1-year high of GBX 1,823.50 ($22.76). The stock has a 50 day moving average price of GBX 1,351.15 and a 200-day moving average price of GBX 1,457.70.

Insiders Place Their Bets

In other GSK news, insider Jonathan Symonds bought 1,500 shares of the business’s stock in a transaction on Friday, December 20th. The stock was purchased at an average cost of GBX 1,315 ($16.41) per share, for a total transaction of £19,725 ($24,619.32). Corporate insiders own 1.61% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. JPMorgan Chase & Co. reissued an “underweight” rating on shares of GSK in a research report on Tuesday, January 7th. Berenberg Bank cut their price objective on shares of GSK from GBX 1,820 ($22.72) to GBX 1,600 ($19.97) and set a “buy” rating for the company in a report on Friday, November 29th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of GBX 1,805.83 ($22.54).

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.